Clodronate disodium tetrahydrate
Based on 5 publication(s) in Google Scholar
Clodronate disodium tetrahydrate (Disodium clodronate tetrahydrate) is first-generation bisphosphonate, with anti-osteoporotic, anti-inflammatory and analgesic effects. Clodronate disodium tetrahydrate is a selective, potent, reversible and Cl- competitive vesicular nucleotide transporter (VNUT) inhibitor, with an IC50 of 15.6 nM. Clodronate disodium tetrahydrate inhibits vesicular ATP release from neurons and reduces chronic neuropathic and inflammatory pain.
For research use only. We do not sell to patients.
- Purity: 99.86%
- CAS No.: 88416-50-6
- Formula: CH10Cl2Na2O10P2
- Molecular Weight:360.92
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-107794R
Clodronate disodium tetrahydrate (Standard)
-
HY-11101
Alendronate sodium hydrate
-
HY-W008951
Ethylenediaminetetra(methylenephosphonic acid)
-
HY-A0003
Lenalidomide
-
HY-Y0006
XPhos
-
HY-W011500
TCEP hydrochloride
-
HY-Y0003
(Rac)-BINAP
-
HY-B0302A
Etidronic acid disodium
-
HY-W008548
Di(adamantan-1-yl)phosphine
-
HY-B0302
Etidronic acid
-
HY-W002849
Cyjohnphos
-
HY-W009062
MePhos
Publications Citing Use of MedChemExpress (MCE) Clodronate disodium tetrahydrate
More
Biological Activity
vesicular ATP release[1]
Clodronate disodium tetrahydrate, a first-generation bisphosphonate, significantly attenuates neuropathic and inflammatory pain unrelated to bone abnormalities via inhibition of VNUT, a key molecule for the initiation of purinergic chemical transmission [1].
Clodronate disodium tetrahydrate is an allosteric modulator of VNUT Cl- dependence [1].
Clodronate disodium tetrahydrate acts as antiresorptive in osteoporosis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clodronate disodium tetrahydrate attenuates inflammation via VNUT inhibition [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (22-30 g)[1]
-
Dosage:10 mg/kg
-
Administration:Intravenous injection
-
Result:Attenuated carrageenan- or complete Freund’s adjuvant (CFA)-evoked inflammatory pain.
Chemical Information
-
CAS No. 88416-50-6
-
Appearance Solid
-
Molecular Weight 360.92
-
Formula CH10Cl2Na2O10P2
-
Color White to off-white
-
SMILES
O=P(C(Cl)(Cl)P(O)(O[Na])=O)(O)O[Na].O.O.O.O
-
Synonyms
Disodium clodronate tetrahydrate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Nat Neurosci
Spatiotemporally selective astrocytic ATP dynamics encode injury information sensed by microglia following brain injury in mice. [Abstract]2024 Aug;27(8):1522-1533. PMID: 38862791 -
ACS Nano
Localized Depletion of Macrophages by Abdominal Cavity Retention Nanoparticles as a Potential Therapy for Peritoneal Metastasis. [Abstract]2026 Jun 16;20(23):16987-17000. PMID: 42225301 -
J Adv Res
Dual regulation of phaseol on osteoclast formation and osteoblast differentiation by targeting TAK1 kinase for osteoporosis treatment. [Abstract]2024 Dec 9:S2090-1232(24)00565-4. PMID: 39662728 -
Phytomedicine
Glycyrol alleviates osteoporosis through dual modulation on osteoclastogenesis and osteogenesis by targeting Syk signaling pathway. [Abstract]2025 Mar:138:156429. PMID: 39939034 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618
Solvent & Solubility
H2O : 116.67 mg/mL (323.26 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 25 mg/mL (69.27 mM); Clear solution; Need ultrasonic and warming
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (701 KB)
- English - EN (701 KB)
- Français - FR (701 KB)
- Deutsch - DE (701 KB)
- Norwegian - NO (701 KB)
- Español - ES (701 KB)
- Swedish - SV (701 KB)
- Italian - IT (701 KB)
- Korean - KR (701 KB)
- Portuguese - PT (701 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kato Y, et al. Identification of a vesicular ATP release inhibitor for the treatment of neuropathic and inflammatory pain. Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):E6297-E6305. [Content Brief]
[2]. Moriyama Y, et al. Clodronate: A Vesicular ATP Release Blocker. Trends Pharmacol Sci. 2018 Jan;39(1):13-23. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.7707 mL | 13.8535 mL | 27.7070 mL | 69.2674 mL |
| 5 mM | 0.5541 mL | 2.7707 mL | 5.5414 mL | 13.8535 mL | |
| 10 mM | 0.2771 mL | 1.3853 mL | 2.7707 mL | 6.9267 mL | |
| 15 mM | 0.1847 mL | 0.9236 mL | 1.8471 mL | 4.6178 mL | |
| 20 mM | 0.1385 mL | 0.6927 mL | 1.3853 mL | 3.4634 mL | |
| 25 mM | 0.1108 mL | 0.5541 mL | 1.1083 mL | 2.7707 mL | |
| 30 mM | 0.0924 mL | 0.4618 mL | 0.9236 mL | 2.3089 mL | |
| 40 mM | 0.0693 mL | 0.3463 mL | 0.6927 mL | 1.7317 mL | |
| 50 mM | 0.0554 mL | 0.2771 mL | 0.5541 mL | 1.3853 mL | |
| 60 mM | 0.0462 mL | 0.2309 mL | 0.4618 mL | 1.1545 mL | |
| 80 mM | 0.0346 mL | 0.1732 mL | 0.3463 mL | 0.8658 mL | |
| 100 mM | 0.0277 mL | 0.1385 mL | 0.2771 mL | 0.6927 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Clodronate disodium tetrahydrate Related Classifications
HY-107794 Related Classifications
Powered by Bioz